SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001654954-19-003644
Filing Date
2019-03-29
Accepted
2019-03-29 13:20:41
Documents
6
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 mbvx10qa_sep302018.htm 10-Q/A 36410
2 MATERIAL CONTRACTS ex10-1.htm EX-10.1 613934
3 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-1.htm EX-31.1 13096
4 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-2.htm EX-31 13007
5 CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE ex32.htm EX-32 10944
6 IMAGE ex10-1000.jpg GRAPHIC 5090
  Complete submission text file 0001654954-19-003644.txt   695672
Mailing Address 11535 SORRENTO VALLEY ROAD SUITE 400 SAN DIEGO CA 92121
Business Address 11535 SORRENTO VALLEY ROAD SUITE 400 SAN DIEGO CA 92121 8582599405
MABVAX THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001109196 (see all company filings)

IRS No.: 930987903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-37861 | Film No.: 19715326
SIC: 2834 Pharmaceutical Preparations